MX2024005057A - Anticuerpo de receptor 4 de efrina tipo a (anti-epha4). - Google Patents

Anticuerpo de receptor 4 de efrina tipo a (anti-epha4).

Info

Publication number
MX2024005057A
MX2024005057A MX2024005057A MX2024005057A MX2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A
Authority
MX
Mexico
Prior art keywords
seq
amino acid
acid sequence
sequence represented
heavy chain
Prior art date
Application number
MX2024005057A
Other languages
English (en)
Spanish (es)
Inventor
Kazuhiro Tahara
Tomomi Kawakatsu
Kazuyoshi Shuta
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2024005057A publication Critical patent/MX2024005057A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
MX2024005057A 2021-11-11 2022-11-09 Anticuerpo de receptor 4 de efrina tipo a (anti-epha4). MX2024005057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021184126 2021-11-11
PCT/JP2022/041723 WO2023085320A1 (ja) 2021-11-11 2022-11-09 抗EphA4抗体

Publications (1)

Publication Number Publication Date
MX2024005057A true MX2024005057A (es) 2024-05-10

Family

ID=86335794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005057A MX2024005057A (es) 2021-11-11 2022-11-09 Anticuerpo de receptor 4 de efrina tipo a (anti-epha4).

Country Status (10)

Country Link
US (1) US20240385190A1 (https=)
EP (1) EP4431606A4 (https=)
JP (1) JPWO2023085320A1 (https=)
KR (1) KR20240099197A (https=)
CN (1) CN118234864A (https=)
AU (1) AU2022388189A1 (https=)
CA (1) CA3235297A1 (https=)
MX (1) MX2024005057A (https=)
TW (1) TW202323286A (https=)
WO (1) WO2023085320A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120988114A (zh) * 2025-08-08 2025-11-21 上海领检科技有限公司 一种人源化IgE嵌合抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗EphA4抗体
JP6877419B2 (ja) * 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
AR119303A1 (es) * 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano

Also Published As

Publication number Publication date
JPWO2023085320A1 (https=) 2023-05-19
US20240385190A1 (en) 2024-11-21
CA3235297A1 (en) 2023-05-19
TW202323286A (zh) 2023-06-16
KR20240099197A (ko) 2024-06-28
AU2022388189A1 (en) 2024-05-02
CN118234864A (zh) 2024-06-21
EP4431606A4 (en) 2025-11-26
WO2023085320A1 (ja) 2023-05-19
EP4431606A1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
MX2022015133A (es) Anticuerpo humanizado anti-receptor de igf-1.
CO2017010316A2 (es) Anticuerpo monoclonal aislado y / o recombinante y un método para identificar la infección por el virus de chikungunya glycoprotein e2 mediante el contacto con una muestra con un anticuerpo o fragmento de anticuerpos con secuencias cdr de cadena pesada y ligera
ES2566501T3 (es) Detección del consumo de cannabis
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20110797A1 (es) Anticuerpos anti mn
RU2016116773A (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
EP4675278A3 (en) Assay for plasma cell associated disease
MX2024001067A (es) Composicion farmaceutica y uso.
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
PE20181051A1 (es) Anticuerpo anti-epha4
PE20180576A1 (es) ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh
WO2018167141A3 (en) Target detection using a monovalent antibody
MX2024005057A (es) Anticuerpo de receptor 4 de efrina tipo a (anti-epha4).
PE20200173A1 (es) Anticuerpos anti-trkb
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
AR087485A1 (es) Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
AR117548A1 (es) Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
EA201692071A1 (ru) Иммуноанализ и антитела для обнаружения хромогранина а